Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.98 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.79 |
| ▸ | ACE | P12821 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | FAP | Q12884 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15024075 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE | |
| Phosphoric Acid SCHEMBL14687437 | 0.96 | DPP4 (0.93) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL15042309 | 0.87 | DPP4 (0.85) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL2667449 | 0.87 | DPP4 (0.78) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin SCHEMBL31513245 | 0.86 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin SCHEMBL29365085 | 0.86 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin SCHEMBL17783 | 0.86 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin SCHEMBL29421658 | 0.86 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin SCHEMBL1289311 | 0.86 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin SCHEMBL174489 | 0.86 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158265-A1 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF | USV LIMITED (IN) | 2013-06-20 | — | — | US | claimed |
| EP-2547683-B1 | METHOD OF PREPARING SITAGLIPTIN | ZENTIVA KS (CZ) | 2014-02-19 | — | — | EP | disclosed |
| US-20130158265-A1 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF | USV LIMITED (IN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158265-A1 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF | USV LIMITED (IN) | 2013-06-20 | — | — | US | disclosed |
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| WO-2011113399-A1 | METHOD OF PREPARING SITAGLIPTIN | ZENTIVA, K.S. (CZ) | 2011-09-22 | — | — | WO | disclosed |
| US-7906503-B2 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | disclosed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | disclosed |
| US-7816364-B2 | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7728141-B2 | Substituted naphthyridinone derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090069284-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| US-7485732-B2 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK & CO., INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2004110375-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2003004498-A1 | BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) PYRAZINES AND TETRAHYDROTRIOAZOLO (4, 3-A) PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | GPR119, GLP1R, GPR4 | DPP4 5/4885DPP8 35/4885DPP7 16/4885 |
| US-20130158265-A1 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF | DPP4, DPP3, DPP9 | DPP4 1/4885DPP8 5/4885DPP7 4/4885 |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | CYP17A1, SHBG, CYP21A2 | DPP4 158/4885DPP8 378/4885DPP7 263/4885 |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | GPR119, GLP1R, GPR4 | DPP4 5/4885DPP8 35/4885DPP7 16/4885 |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | CYP17A1, SHBG, CYP21A2 | DPP4 158/4885DPP8 378/4885DPP7 263/4885 |
| US-20090069284-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | CNR1, CNR2, MAG | DPP4 1435/4885DPP8 2304/4885DPP7 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.